m+Medelevator.RU
← Поиск публикаций
Cell reports · 2026

Complex I drives glutamine-dependent TCA cycle to support viability of MYChigh breast cancer cells.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Anttila Johanna M, Savelius Mariel, Id Linda, Nicorici Daniel, Somani Juhi, Hiltunen Antti O, Munne Pauliina M, Peura Aino, Peltonen Martina, Aung July, Awadhpersad Ryan, Nyhamar Ellisiv, Prajapati Bina, Ala-Hongisto Hanna, Gautam Prson, Välimäki Mika J, Tervonen Topi A, Šapovalovaitė Karina, Devarajan Raman, Ruiz Pérez María Victoria, Mutka Minna, Kovanen Panu, Niinikoski Laura, Meretoja Tuomo, Mattson Johanna, Heikkilä Päivi, Wennerberg Krister, Arsenian-Henriksson Marie, Westermarck Jukka, Aittokallio Tero, Goga Andrei, Jackson Christopher B, Nieminen Anni I, Klefström Juha

Аннотация

In many cancers, stably elevated MYC levels drive sustained activation of anabolic programs and the cell cycle, creating opportunities for the synthetic-lethal targeting of MYChigh tumors. Enhanced mitochondrial respiration is a hallmark of MYC overexpressing cancer cells. Mitochondrial respiration sustains the TCA cycle by regenerating NAD+ through complex I-mediated oxidation of NADH, supporting the anabolic demand of MYC-driven cells. Metabolic carbon tracing reveals that MYC shifts the TCA cycle carbon source from glucose to glutamine. Inhibition of the glutamine-fueled TCA cycle using NAD+-depleting complex I inhibitors promotes MYC-dependent synthetic lethality in breast cancer cells. In mouse models of MYChigh tumors, combined inhibition of complex I and glutaminolysis produces persistent suppression of tumor growth. Altogether, the elevated respiration of MYChigh cells supports a glutamine carbon-enriched TCA cycle that meets anabolic demand, rendering MYChigh tumors selectively vulnerable to mitochondrial respiration and glutaminolysis inhibitors.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты